A global community of physicians cooperated to share experiences with systemic drugs for pediatric psoriasis, and to get experience with a joint registry. A uniform dataset could be tapped to learn more about disease manifestations and treatment outcomes
Treatments for Plaque Psoriasis
Psoriatic arthritis can often go undiagnosed in patients with psoriasis, and an earlier diagnosis is critical to prevent the adverse effects of psoriatic arthritis, according to an expert.
The approval of abatacept (Orencia/Bristol-Myers Squibb) for psoriatic arthritis (PsA) earlier this month by the FDA offers a new treatment option for patients who are struggling to keep the disease under control.
A novel cell-based strategy tested in mice can detect the onset of psoriasis flares by measuring disease biomarkers and then release therapeutic proteins to stop progression. Future implications are exciting.
As research advances understanding of psoriasis, drug development evolves to address various pathways to disease. A number of possibilities, now in clinical trials, appear safe, effective and promising with improved long-term clearance rates.
Newer medications have revolutionized psoriasis care in patients with moderate-to-severe cases, says a leading dermatologist, and more drugs in the pipeline promise to offer even more choices.
Researchers have uncovered new information about the pathogenetic similarities and differences between cutaneous psoriasis and psoriatic arthritis in a recent study. They hope the information, one day, leads to a test to help doctors determine which psoriasis patients will advance with psoriatic disease.
Indigo naturalis is an Old-World plant with multiple uses. Used in China for centuries as a traditional medicine, current clinical studies are proving its effectiveness as well as identifying mechanisms of action.
Dermatologists could be making greater use of topical retinoids and vitamin D preparations in treating a variety of hyperproliferative and other skin disorders. In the early days of psoriasis treatment, the “sandwich theory” focused on epidermal turnover and inflammation, with one drug or strategy for each layer.
Although many systemic immunomodulators are approved for psoriasis, their mechanisms of action suggest they have utility in indications ranging from atopic dermatitis (AD) to chronic urticaria. Understanding a systemic immunomodulator’s mechanism of action provides a theoretical basis for uses beyond its labeled indication.